Both tesamorelin and sermorelin are growth hormone-releasing hormone (GHRH) analogs, but they differ significantly in their clinical focus, potency, and regulatory status. They stimulate the pituitary gland to release endogenous growth hormone (GH) in a pulsatile manner.
Tesamorelin: Targeted Fat Loss
Tesamorelin is a stabilized GHRH analog with a longer half-life. It is uniquely studied and FDA-approved (as Egrifta) for the reduction of visceral adipose tissue (VAT)—the deep abdominal fat that surrounds internal organs. It is generally considered more potent due to its resistance to enzymatic degradation.
Sermorelin: General Vitality
Sermorelin is a 29-amino acid fragment of naturally occurring GHRH. It is traditionally used for general GH stimulation, recovery support, and sleep quality improvement. It has a shorter half-life and typically requires consistent daily administration. It is often preferred for general wellness due to its long history of use and lower cost profile.
Clinical Safety Framing: Risk, contraindications, interactions, and follow-up planning should be reviewed before initiating any peptide pathway.